Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS)

PsA and AS are long-term, debilitating conditions which affect the joints and spine¹⁻³

WHAT IS PsA?4,5

PsA is a long lasting inflammatory disease linked with significant disability. poor quality of life and reduced life expectancy. PsA is closely associated with psoriasis.

AFFECTED BODY PARTS⁶








SKIN AND NAILS



WHAT IS AS?7-10

A long lasting inflammatory disease of the joints. Up to 70% of patients with severe AS can develop spinal fusion (bones grow together), significantly reducing mobility and quality of life.

AFFECTED BODY PARTS¹¹



COMMON **DISEASE** SYMPTOMS^{12,13}











EFFECTS ON QUALITY OF LIFE^{5,13}









TREATMENT^{12,14}

The current standard of care for PsA and AS is anti-tumor-necrosis-factor (anti-TNF) medicines. However, nearly half of patients are dissatisfied with these therapies and up to 40% have inadequate or no response to treatment, indicating a significant unmet need.





















^{11.} National Ankylosing Spondylitis Society (UK) website. Accessed October 2014.

12. Dougados M, Baeten D. Lancet. 2011;377:2127-37.

13. Martindale J et al., Rheumatology (Oxford), 2006;45(10):1288-93.

14. Armstrong A et al., JAMA Dermatol. 2013;149(10):1180-1185.



^{1.} Helmick CG et al. Arthritis Rheum. 2008;58:15-25.
2. Reveille JD et al. Arthritis Care Res. 2012;64:905-10. (NHAMES 1)
3. Strand V et al. Arthritis Care Res. 2013;65(9):1299-306
4. Turkiewicz et al. Arthritis Rheum. 2007;56(4):1051-1066.
5. Lee S et al. 2010;35(12):680-689.

^{7.} American Cippego of Rheumatology (ACR) website. Accessed October 2014.
8. Sieper J. et al. Ann Rheum Dis. 2002;6 (Suppl III);iii8-iii18.
9. Lories R. Nat Rev Rheumatol. 2017;770-07.
10. Barkham N et al. Rheumatology. 2005;44:1277-81.